A. Bisconte

发表

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling

J. M. Bradshaw, A. Zarbock, A. Margraf, 2018, British journal of pharmacology.

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

J. M. Bradshaw, A. Johnson, P. Porcu, 2014, The Journal of Biological Chemistry.

Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.

Steve Price, A. Nadin, BinQing Wei, 2013, Bioorganic & medicinal chemistry letters.

Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus.

D. Murrell, D. Borjesson, S. Gourlay, 2020, Veterinary dermatology.

Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus.

D. Murrell, D. Borjesson, S. Gourlay, 2020, Veterinary dermatology.

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

J. M. Bradshaw, E. Verner, D. Goldstein, 2022, Journal of medicinal chemistry.

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

J. M. Bradshaw, D. Goldstein, C. Langrish, 2021, The Journal of Immunology.

Efficacy in collagen induced arthritis models with a selective, reversible covalent Bruton’s tyrosine kinase inhibitor PRN473 is driven by durable target occupancy rather than extended plasma exposure (THER5P.904)

J. Funk, E. Verner, D. Goldstein, 2015, The Journal of Immunology.

The Bruton's tyrosine kinase inhibitor PRN473 inhibits neutrophil recruitment via inhibition of Mac-1 signaling

A. Zarbock, A. Margraf, C. Lowell, 2017 .

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. M. Bradshaw, Jack Taunton, Sergei Romanov, 2015, Nature chemical biology.

Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

J. M. Bradshaw, Dachuan Huang, C. Ong, 2018, Leukemia.

Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.

Steve Price, BinQing Wei, D. Sutherlin, 2013, Bioorganic & medicinal chemistry letters.

Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero.

Christopher H Contag, Gerald S Lipshutz, C. Contag, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

A new treatment for autoimmune blistering diseases- the efficacy of Bruton's tyrosinase kinase inhibitor PRN473 in canine pemphigus foliaceus

D. Murrell, D. Borjesson, S. Gourlay, 2016 .